We are live on ! Find out more
BLRX

BioLineRX
BLRX

25 hedge funds and large institutions have $26.9M invested in BioLineRX in 2015 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 1

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

194% more capital invested

Capital invested by funds: $9.16M → $26.9M (+$17.8M)

67% more funds holding

Funds holding: 15 → 25 (+10)

Holders
25
Holders Change
+10
Holders Change %
+66.67%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
5
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$6.36M
2
SM
Senvest Management
New York
+$2.15M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.54M
4
Millennium Management
Millennium Management
New York
+$896K
5
Deutsche Bank
Deutsche Bank
Germany
+$663K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$378K
2
Renaissance Technologies
Renaissance Technologies
New York
-$44K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
– -$44K -45 Closed
1
2

BLRX Hedge Fund Activity: Q1 2015 in Review

25 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2015, worth a combined $26.9M — up 194% from $9.16M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new BLRX positions and 1 closed out — a net gain of 10 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Broadfin Capital, opening a new position worth an estimated $6.36M. The largest seller was Sabby Management, cutting an estimated $378K.

  • 25 institutional investors held BioLineRX (BLRX) as of Q1 2015, up from 15 in Q4 2014.
  • Funds reported $26.9M of BioLineRX stock for Q1 2015, up 194% quarter-over-quarter.
  • 11 funds opened new BioLineRX positions in Q1 2015 and 1 closed out, a net change of +10 holders.
  • The largest BioLineRX buyer in Q1 2015 was Broadfin Capital, an estimated $6.36M added.
  • The largest BioLineRX seller in Q1 2015 was Sabby Management, an estimated $378K sold.

Based on aggregated 13F filings for Q1 2015.